These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27797594)

  • 21. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
    Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
    Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Farletuzumab in epithelial ovarian carcinoma.
    Spannuth WA; Sood AK; Coleman RL
    Expert Opin Biol Ther; 2010 Mar; 10(3):431-7. PubMed ID: 20092424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
    Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
    Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
    Manning-Geist BL; Sullivan MW; Zhou Q; Iasonos A; Selenica P; Stallworth C; Liu YL; Long Roche K; Gordhandas S; Aghajanian C; Chi D; O'Cearbhaill R; Grisham RN; Chui MH
    Gynecol Oncol; 2024 Sep; 188():52-57. PubMed ID: 38941962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
    Bogani G; Coleman RL; Vergote I; van Gorp T; Ray-Coquard I; Oaknin A; Matulonis U; O'Malley D; Raspagliesi F; Scambia G; Monk BJ
    Int J Gynecol Cancer; 2024 Apr; 34(4):469-477. PubMed ID: 38101816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
    Moore KN; Angelergues A; Konecny GE; García Y; Banerjee S; Lorusso D; Lee JY; Moroney JW; Colombo N; Roszak A; Tromp J; Myers T; Lee JW; Beiner M; Cosgrove CM; Cibula D; Martin LP; Sabatier R; Buscema J; Estévez-García P; Coffman L; Nicum S; Duska LR; Pignata S; Gálvez F; Wang Y; Method M; Berkenblit A; Bello Roufai D; Van Gorp T;
    N Engl J Med; 2023 Dec; 389(23):2162-2174. PubMed ID: 38055253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-drug conjugates in gynecologic malignancies.
    Lee EK; Liu JF
    Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.
    Vergote IB; Marth C; Coleman RL
    Cancer Metastasis Rev; 2015 Mar; 34(1):41-52. PubMed ID: 25564455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
    Konner JA; Bell-McGuinn KM; Sabbatini P; Hensley ML; Tew WP; Pandit-Taskar N; Vander Els N; Phillips MD; Schweizer C; Weil SC; Larson SM; Old LJ
    Clin Cancer Res; 2010 Nov; 16(21):5288-95. PubMed ID: 20855460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer.
    Kokori E; Olatunji G; Komolafe R; Abraham IC; Ukoaka B; Samuel O; Ayodeji A; Ogunbowale I; Ezenwoba C; Aderinto N
    Medicine (Baltimore); 2024 May; 103(20):e38132. PubMed ID: 38758856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro.
    Kamen BA; Smith AK
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):113-20. PubMed ID: 22644798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trials and future potential of targeted therapy for ovarian cancer.
    Itamochi H; Kigawa J
    Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.
    Lin J; Spidel JL; Maddage CJ; Rybinski KA; Kennedy RP; Krauthauser CL; Park YC; Albone EF; Jacob S; Goserud MT; Martinez BP; Chao Q; Zhou Y; Nicolaides NC; Kline JB; Grasso L
    Cancer Biol Ther; 2013 Nov; 14(11):1032-8. PubMed ID: 24025360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.
    Rudman SM; Josephs DH; Cambrook H; Karagiannis P; Gilbert AE; Dodev T; Hunt J; Koers A; Montes A; Taams L; Canevari S; Figini M; Blower PJ; Beavil AJ; Nicodemus CF; Corrigan C; Kaye SB; Nestle FO; Gould HJ; Spicer JF; Karagiannis SN
    Clin Exp Allergy; 2011 Oct; 41(10):1400-13. PubMed ID: 21569129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
    Cheng X; Li J; Tanaka K; Majumder U; Milinichik AZ; Verdi AC; Maddage CJ; Rybinski KA; Fernando S; Fernando D; Kuc M; Furuuchi K; Fang F; Uenaka T; Grasso L; Albone EF
    Mol Cancer Ther; 2018 Dec; 17(12):2665-2675. PubMed ID: 30262588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enthusiasm for antibody-drug conjugates.
    Tuma RS
    J Natl Cancer Inst; 2011 Oct; 103(20):1493-4. PubMed ID: 21972230
    [No Abstract]   [Full Text] [Related]  

  • 37. Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?
    Birrer MJ; Betella I; Martin LP; Moore KN
    Oncologist; 2019 Apr; 24(4):425-429. PubMed ID: 30635448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
    Yam C; Rauch GM; Rahman T; Karuturi M; Ravenberg E; White J; Clayborn A; McCarthy P; Abouharb S; Lim B; Litton JK; Ramirez DL; Saleem S; Stec J; Symmans WF; Huo L; Damodaran S; Sun R; Moulder SL
    Invest New Drugs; 2021 Apr; 39(2):509-515. PubMed ID: 32984932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
    Matulonis UA; Birrer MJ; O'Malley DM; Moore KN; Konner J; Gilbert L; Martin LP; Bauer TM; Oza AM; Malek K; Pinkas J; Kim SK
    Clin Cancer Res; 2019 Mar; 25(6):1727-1736. PubMed ID: 30413525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic strategies targeting folate receptor α for ovarian cancer.
    Mai J; Wu L; Yang L; Sun T; Liu X; Yin R; Jiang Y; Li J; Li Q
    Front Immunol; 2023; 14():1254532. PubMed ID: 37711615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.